spesolimab sold brand name spevigo monoclonal antibody used treatment generalized pustular psoriasis receptor given via injection common adverse reactions include fatigue nausea vomiting headache pruritus itching prurigo itchy bumps bruising urinary tract approved medical use united states september european union december us food drug administration fda considers firstinclass spesolimab indicated treatment generalized pustular psoriasis flares us food drug administration fda approved spesolimab based evidence clinical trial adults generalized pustular psoriasis trial conducted three sites united states sites globally africa asia spesolimab evaluated one clinical trial study adults generalized pustular psoriasis trial participants received single treatment either spesolimab participants evaluated clearance pustules based generalized pustular psoriasis physician global assessment gpppga pustulation sub score indicating visible pustules week neither participant healthcare providers knew treatment given week week participants whether initially received spesolimab placebo continued experience flare symptoms option receive single openlabel treatment spesolimab second treatment first treatment participants spesolimab placebo groups week week participants either original treatment group whose generalized pustular psoriasis flare reoccurred achieving clinical response eligible receive single openlabel rescue treatment spesolimab maximum three total treatments spesolimab throughout october committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting conditional marketing authorization medicinal product spevigo intended treatment flares adult patients generalised pustular applicant medicinal product boehringer ingelheim international spesolimab approved medical use european union december immune activation dostarlimab ibalizumab pharmacologyrelated article stub help wikipedia expanding httpsenwikipediaorgwikispesolimab